A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Guardant Health, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 66,200 shares of GH stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,200
Previous 880,800 92.48%
Holding current value
$1.68 Million
Previous $18.2 Million 89.48%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$16.07 - $31.84 $8.04 Million - $15.9 Million
500,359 Added 17.93%
3,290,897 $95 Million
Q1 2024

May 15, 2024

BUY
$17.13 - $26.91 $47.3 Million - $74.3 Million
2,762,668 Added 9912.69%
2,790,538 $57.6 Million
Q4 2023

Feb 14, 2024

SELL
$21.58 - $29.5 $8.86 Million - $12.1 Million
-410,445 Reduced 93.64%
27,870 $753,000
Q3 2023

Nov 14, 2023

BUY
$25.8 - $39.97 $733,184 - $1.14 Million
28,418 Added 6.93%
438,315 $13 Million
Q2 2023

Aug 14, 2023

BUY
$20.94 - $38.01 $2.99 Million - $5.43 Million
142,831 Added 53.48%
409,897 $14.7 Million
Q1 2023

May 15, 2023

SELL
$22.92 - $33.76 $379,830 - $559,470
-16,572 Reduced 5.84%
267,066 $6.26 Million
Q4 2022

Feb 14, 2023

SELL
$25.44 - $59.78 $1.74 Million - $4.08 Million
-68,214 Reduced 19.39%
283,638 $7.71 Million
Q3 2022

Nov 14, 2022

BUY
$43.66 - $61.0 $9.43 Million - $13.2 Million
216,050 Added 159.09%
351,852 $18.9 Million
Q2 2022

Aug 15, 2022

SELL
$28.82 - $77.35 $11.5 Million - $30.8 Million
-398,623 Reduced 74.59%
135,802 $5.48 Million
Q1 2022

May 16, 2022

BUY
$48.25 - $100.49 $707,779 - $1.47 Million
14,669 Added 2.82%
534,425 $35.4 Million
Q4 2021

Feb 14, 2022

BUY
$88.71 - $120.43 $31.3 Million - $42.5 Million
353,092 Added 211.86%
519,756 $52 Million
Q2 2021

Aug 16, 2021

SELL
$109.77 - $165.68 $8.77 Million - $13.2 Million
-79,867 Reduced 32.4%
166,664 $20.7 Million
Q1 2021

May 17, 2021

SELL
$127.04 - $179.1 $4.87 Million - $6.87 Million
-38,356 Reduced 13.46%
246,531 $37.6 Million
Q4 2020

Feb 16, 2021

BUY
$99.96 - $135.93 $4.43 Million - $6.03 Million
44,351 Added 18.44%
284,887 $36.7 Million
Q3 2020

Nov 16, 2020

BUY
$80.32 - $111.8 $14.3 Million - $19.9 Million
178,206 Added 285.91%
240,536 $26.9 Million
Q2 2020

Aug 14, 2020

SELL
$60.49 - $97.5 $3.89 Million - $6.28 Million
-64,367 Reduced 50.8%
62,330 $5.06 Million
Q1 2020

May 15, 2020

BUY
$59.04 - $88.81 $4.83 Million - $7.27 Million
81,876 Added 182.67%
126,697 $8.82 Million
Q4 2019

Feb 14, 2020

SELL
$59.49 - $82.78 $4.64 Million - $6.46 Million
-78,024 Reduced 63.51%
44,821 $3.5 Million
Q3 2019

Nov 14, 2019

BUY
$62.59 - $110.3 $2.86 Million - $5.05 Million
45,771 Added 59.39%
122,845 $7.84 Million
Q2 2019

Aug 14, 2019

SELL
$63.94 - $91.11 $981,351 - $1.4 Million
-15,348 Reduced 16.61%
77,074 $6.65 Million
Q1 2019

May 15, 2019

BUY
$34.3 - $97.98 $3.17 Million - $9.06 Million
92,422 New
92,422 $0

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $2.6B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.